Table 1.
Studies evaluating the efficacy of IDegLira and IGlarLixi in patients with diabetes mellitus type 2 inadequately controlled with oral medication and insulin naive
| Study | DUAL-1 | LixiLan-O | ||||
|---|---|---|---|---|---|---|
| IDegLira | Degludec | Liraglutide | IGlarLixi | Glargine U100 | Lixisenatide | |
| Duration | 26 weeks | 30 weeks | ||||
| Population | 1663 T2DM adults, A1c 8.3 ± 0.9; BMI 31.2 ± 4.8 kg/m2, metformin ± pioglitazone | 1170 T2DM adults, A1c 8.2 ± 0.7; BMI 31.7 ± 4.4 kg/m2; metformin ± pioglitazone | ||||
| Mean insulin dose (final) | 38 ± 13 | 53 ± 28 | 39 ± 14 | 40 ± 14 | ||
| ΔA1c | − 1.9 ± 1.1 | − 1.4 ± 1.0 | − 1.3 ± 1.1 | − 1.6 ± 0.1 | − 1.3 ± 0.1 | − 0.8 ± 0.1 |
| Final A1c (week 30) | 6.4 ± 1.0 | 6.9 ± 1.1 | 7.0 ± 1.2 | 6.5 ± 0.8 | 6.8 ± 0.8 | 7.3 ± 0.9 |
| Δ body weight (kg) | − 0.5 ± 3.5 | + 1.6 ± 4.0 | − 3.0 ± 3.5 | − 0.3 ± 0.2 | + 1.1 ± 0.2 | − 2.3 ± 0.3 |
| % A1c < 7% | 81 | 65 | 60 | 74 | 59 | 33 |
| %A1c < 7% without weight gain | 46 | 21 | 54 | 43 | 25 | 28 |
| %A1c < 7% without hypoglycemia | 60 | 41 | 58 | 53 | 44 | 30 |
| %A1c < 7% without weight gain or hypoglycemia | 36 | 14 | 52 | 32 | 19 | 26 |
| Hypoglycemia (%)a | 32 | 39 | 7 | 26 | 24 | 6 |
aDifferent definitions for hypoglycaemia were used in the two studies. For the DUAL I trial, confirmed hypoglycaemia was defined as the occurrence of episodes requiring assistance (severe), or episodes in which plasma glucose concentration (determined from self-monitored blood glucose) was less than 56 mg/dL, irrespective of symptoms. For the LixiLan-O trial, documented symptomatic hypoglycemia was defined as typical symptoms of hypoglycaemia accompanied by a measured plasma glucose concentration of #70 mg/dL